Breaking News Instant updates and real-time market news.

IMMU

Immunomedics

$3.36

-0.11 (-3.17%)

09:03
11/29/16
11/29
09:03
11/29/16
09:03

venBio responds to Immunomedics' postponement of annual meeting

venBio Select Advisor, the beneficial owner of approximately 9.5 million shares, or 9.0%, of Immunomedics, Inc. and its largest stockholder, issued the following statement regarding the company's sudden announcement that it will postpone its Annual Meeting, which was originally scheduled for December 14, 2016, to February 16, 2017: "Immunomedics' decision to postpone its Annual Meeting does a severe disservice to the Company's stockholders. We believe investors deserve the opportunity to voice, without delay, their frustration at the strategic missteps of the Company's leadership. By denying stockholders their right to elect directors this year, we believe the Company is simply perpetuating the pattern of self-serving actions and value destruction that have characterized Immunomedics to date. Further, we note that Immunomedics' delay of the meeting is a clear violation of Delaware corporate law, as the new meeting would be more than the permissible 13 month period since the prior meeting on December 2, 2015. As such, we are considering all options for protecting stockholders' rights under applicable law. Importantly, we are also concerned that management, in their push to show 'progress', could make rash decisions that will prove detrimental to the Company and to all stockholders. 'Fast-tracking' any purported deal or partnership to show "progress", would raise the question of whether this board really cares more about what is best for the value and future of the Company or preserving their own positions. The only thing that has changed ahead of the Company's attempts to outline its strategy going forward has been our public involvement. We believe that this speaks to the fact that the Company felt no need to make progress on these fronts until feeling the brunt of public pressure. In our view, Immunomedics is merely paying lip service to the concerns of its investor base, and lacks the ability and willingness to effect meaningful change. We of course appreciate the Company saying that they are open to engagement with us, and remain receptive to any ideas they put forth. However, we continue to believe that Immunomedics must truly commit to transformative change that is in the best interests of all stockholders. Furthermore, the Company's excuse that it is delaying the meeting to give stockholders the opportunity to evaluate the Company's progress is absurd. Stockholders have already had a full year to evaluate progress since the last annual meeting and should be allowed to exercise their right to vote without delay. The incumbent Board should not prioritize its desire to stay in office over the rights of its stockholders. At this point, Immunomedics has had ample time to make meaningful changes that would set the Company on the path towards success. It is time to choose the path of experience, competence and value creation, rather than the path of stagnation, management self-enrichment and shareholder value destruction. We urge all stockholders to vote FOR all four of our Nominees on the GOLD proxy card as soon as it becomes available."

  • 03

    Dec

  • 14

    Dec

  • 16

    Feb

IMMU Immunomedics
$3.36

-0.11 (-3.17%)

05/06/16
JEFF
05/06/16
UPGRADE
Target $5
JEFF
Buy
Immunomedics upgraded to Buy from Hold at Jefferies
Jefferies analyst Chris Howerton upgraded Immunomedics to Buy saying IMMU-132 continues to demonstrate impressive clinical data in solid tumors. The analyst sees a greater likelihood of Immunomedics securing a partner for the asset following recent data. He raised his price target for the shares to $5.00 from $1.50.
06/21/16
WELS
06/21/16
DOWNGRADE
WELS
Market Perform
Immunomedics downgraded to Market Perform from Outperform at Wells Fargo
10/06/16
JEFF
10/06/16
INITIATION
Target $5.5
JEFF
Buy
Immunomedics assumed with a Buy at Jefferies
Jefferies analyst Matthew Andrews assumed coverage of Immunomedics with a Buy rating and raised his price target for the shares to $5.50 from $5. IMMU-132's "promising results" in Triple Negative breast cancer sets the stage for a partnership deal in the coming months, Andrews tells investors in a research note.
10/18/16
JEFF
10/18/16
NO CHANGE
JEFF
Jefferies sees 'attractive buying opportunities' in Biotech
The Jefferies Biotechnology team sees "attractive buying opportunities" amidst the pre-election weakness. While volatility will likely continue into the election, valuation multiples are near-historic lows and policy concerns, while valid, are likely overstated, the analysts tell investors in a research note. They recommend using the weakness to buy select names ahead of a potential improvement in sentiment. Jefferies likes Gilead (GILD) and Celgene (CELG) among large-caps, The Medicines Co. (MDCO), Alkermes (ALKS) and Vertex (VRTX) among mid-caps, and Alder Biopharmaceuticals (ALDR), Cempra (CEMP), Ultragenyx (RARE) and Immunomedics (IMMU) among small-caps.

TODAY'S FREE FLY STORIES

NFLX

Netflix

$227.58

7.12 (3.23%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

HSGX

Histogenics

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Syndicate
Breaking Syndicate news story on Histogenics »

Histogenics 2.34M share…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

GAIA

Gaia

$11.90

-0.05 (-0.42%)

07:21
01/23/18
01/23
07:21
01/23/18
07:21
Conference/Events
Gaia management to meet with B. Riley »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

07:20
01/23/18
01/23
07:20
01/23/18
07:20
General news
Treasury Market Outlook: global yields tracked lower overnight »

Treasury Market Outlook:…

07:18
01/23/18
01/23
07:18
01/23/18
07:18
Conference/Events
Federal Reserve Bank of Chicago President participates in a discussion »

Chicago Federal Reserve…

STT

State Street

$108.99

1.38 (1.28%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Hot Stocks
State Street sees Beacon savings realized 18 months ahead of plan by mid-2019 »

In slides ahead of its Q4…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Conference/Events
The Chicago Council on Global Affairs to hold a panel discussion »

The Chicago Council on…

W

Wayfair

$90.64

2.8 (3.19%)

07:17
01/23/18
01/23
07:17
01/23/18
07:17
Downgrade
Wayfair rating change  »

Wayfair downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

07:16
01/23/18
01/23
07:16
01/23/18
07:16
Conference/Events
CFA Society of Columbus to hold a dinner meeting »

Ian Wallace of Third…

VYGR

Voyager Therapeutics

$20.23

1.56 (8.36%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Hot Stocks
Voyager Therapeutics announces FDA clearance of VY-AADC IND application »

Voyager Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TBK

Triumph Bancorp

$37.00

1 (2.78%)

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Upgrade
Triumph Bancorp rating change  »

Triumph Bancorp upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

07:13
01/23/18
01/23
07:13
01/23/18
07:13
Conference/Events
Boston University to release survey »

Boston University…

CAT

Caterpillar

$170.89

0.48 (0.28%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Upgrade
Caterpillar rating change  »

Caterpillar upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

GPRO

GoPro

$6.30

0.01 (0.16%)

07:12
01/23/18
01/23
07:12
01/23/18
07:12
Downgrade
GoPro rating change  »

GoPro downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:11
01/23/18
01/23
07:11
01/23/18
07:11
Periodicals
Verizon mulls sports gambling as legalization nears, Bloomberg reports »

Verizon is mulling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

, JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Recommendations
Sorrento Therapeutics, Juno Therapeutics, Celgene analyst commentary  »

Juno acquisition bodes…

SRNE

Sorrento Therapeutics

$7.75

1.35 (21.09%)

JUNO

Juno Therapeutics

$86.00

18.19 (26.83%)

CELG

Celgene

$102.91

0.26 (0.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

  • 25

    Jan

  • 29

    Jan

  • 16

    Feb

  • 28

    Feb

  • 25

    Mar

SPX

S&P 500

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Technical Analysis
S&P 500: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

, ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Conference/Events
U.S. Capital Advisors to hold a conference »

Midstream Corporate…

ENLC

EnLink Midstream

$19.25

0.5 (2.67%)

ENLK

EnLink Midstream Partners

$18.08

0.63 (3.61%)

TRGP

Targa Resources

$51.00

0.27 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 26

    Feb

ACBFF

Aurora Cannabis

$11.65

0.8799 (8.17%)

07:10
01/23/18
01/23
07:10
01/23/18
07:10
Hot Stocks
Aurora Cannabis, CanniMed extending standstill agreement »

CanniMed Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GDX

Market Vector Gold Miners

$23.71

0.06 (0.25%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
Market Vector Gold Miners: Pivot points, pivot high broken »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Breaking Hot Stocks news story on Verizon »

Verizon up marginally…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

AOS

A.O. Smith

$67.00

-0.04 (-0.06%)

, JCI

Johnson Controls

$39.20

0.3 (0.77%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Conference/Events
KeyBanc to hold company meetings at expo »

KeyBanc Company Meetings…

AOS

A.O. Smith

$67.00

-0.04 (-0.06%)

JCI

Johnson Controls

$39.20

0.3 (0.77%)

RBC

Regal Beloit

$79.20

-0.2 (-0.25%)

WTS

Watts Water

$79.65

-0.85 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 30

    Jan

  • 31

    Jan

  • 06

    Feb

  • 13

    Feb

  • 22

    Feb

VZ

Verizon

$53.46

1.55 (2.99%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Hot Stocks
Verizon sees positive impact to cash flow from operations from tax reform »

Tax-reform legislation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 25

    Jan

GLD

SPDR Gold Trust

$126.65

0.23 (0.18%)

07:09
01/23/18
01/23
07:09
01/23/18
07:09
Technical Analysis
SPDR Gold Trust: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:08
01/23/18
01/23
07:08
01/23/18
07:08
Conference/Events
Goldman Sachs to hold a conference »

Fintech Conference 2018…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.